Develops phage-based solutions to treat bacterial disease and address antibiotic resistance
Develops phage-based solutions to treat bacterial disease and address antibiotic resistance. Its platform combines phage isolation, sequencing of phages and target bacteria, proprietary AI prediction of phage-bacteria interactions, and laboratory validation. The approach has been proven in animal health, with more than three million animals treated, and is being extended to human-health drug discovery partnerships.